INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
13 März 2024 - 1:00PM
INmune Bio Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, announces its Chief Scientific Officer and
Co-Founder Mark Lowdell, Ph.D. has been awarded the Career
Achievement Award in Cell and Gene Therapy by the International
Society of Cell & Gene Therapy (ISCT), which the organization
considers its highest honor. The award was announced as part of the
annual ICST Major Awards announcement. Dr. Lowdell will receive the
award during the organization’s annual meeting in Vancouver on May
29, 2024.
“We congratulate Mark on this important and well-deserved
achievement. The ISCT is the elite organization in the field of
cell and gene therapy,” said R.J. Tesi, M.D., INmune Bio’s Chief
Executive Officer. “I have seen firsthand the disciplined and
thoughtful approach that Mark Lowdell uses to convert complex
science into clinical therapies in the development of
INKmune.”
Mark Lowdell, Ph.D., is CSO and Co-Founder of INmune Bio and
Professor of Cell & Tissue Therapy at University College
London, United Kingdom. With a career spanning 30+ years as a world
leader in translational immunotherapy, his expertise and leadership
in the field have earned him recognition from both the scientific
community and industry. Dr. Lowdell has been responsible for the
development and delivery of multiple cell-based therapies and the
first GMP-compliant embryonic stem-cell derived product in clinical
trials in the UK. Additionally, he established the first academic
GMP facility in the UK to produce human cells as medicines in 2003.
Dr. Lowdell continues to lead and inspire the global CGT community
to advance innovation to drive clinical translation of cell and
gene therapies for the benefit of patients.
“I am honored to receive this most prestigious award in
recognition of my life’s work and wish to thank the members of the
ISCT. My efforts in developing INKmune stem from years of
accumulated knowledge and expertise, with the goal of creating a
scalable cancer immunotherapy that can be easily delivered to a
large number of patients without the need for complex logistics.
The experience gained during my career has been instrumental in
creating the industrialized manufacturing process and testing
regimen for INKmune, even at this early stage of clinical
development,” said Dr. Lowdell.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on
developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms that are both in
clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. XPro1595™,
the first of several DN-TNF products, is in clinical trials to
determine if it can treat patients with mild Alzheimer’s
disease. Additional therapeutic indications, including
treatment-resistant depression and oncology will be pursued when
resources allow. The Natural Killer Cell Priming Platform includes
INKmune™ , a therapy developed to prime a patient’s NK cells to
treat patients with cancer. INKmune™ uses a precision medicine
approach for the treatment of a wide variety of hematologic and
solid tumor malignancies. The INKmune™ trial is enrolling patients
into a US Phase I/II trial in men with metastatic castrate
resistant prostate cancer. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595™, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO(858) 964-3720info@inmunenbio.com
Investor Contact:Jason Nelson, Core IR(516) 842-9614 x-823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024